Catalog No. size PriceQuantity
M6523-2 2mg solid $100
M6523-10 10mg solid $396


LY-2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) which plays an important role in many pathways, including initiation of protein synthesis, cell proliferation, cell differentiation, and apoptosis. Pre-clinically LY-2090314 i stabilizes β-catenin and enhances the efficacy of platinum based regimens.

Product information

CAS Number: 603288-22-8

Molecular Weight: 512.53

Formula: C28H25FN6O3


LY 2090314



Chemical Name: 3-(9-fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione

Smiles: O=C1NC(=O)C(=C1C1=CN=C2C=CC=CN21)C1C=CC2CNC(CN3C(F)=CC=1C3=2)C(=O)N1CCCCC1


InChi: InChI=1S/C28H25FN6O3/c29-21-12-18-17(23-24(27(37)32-26(23)36)20-14-31-22-6-2-5-11-34(20)22)8-7-16-13-30-19(15-35(21)25(16)18)28(38)33-9-3-1-4-10-33/h2,5-8,11-12,14,19,30H,1,3-4,9-10,13,15H2,(H,32,36,37)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 100 mg/mL(195.11 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

LY-2090314 selectively inhibits the activity of GSK-3 by interrupting ATP binding. LY-2090314 is able to stabilize β-catenin. LY-2090314 shows limited efficacy as monotherapy. LY-3090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer cell lines in vitro.

In Vivo:

LY-2090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer xenografts.


  1. Brail LH, et al. J Clin Oncol, 2011, 29, abstr 3030.
  2. A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin. Meeting: 2011 ASCO Annual Meeting, Presenter: Les H. Brail.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed